SKNV Announces Exclusive Commercialization Rights to Washington University Patent Portfolio Covering Combination of Fluorouracil and Calcipotriene Therapies

Summary

SKNV announced exclusive commercialization rights to a Washington University patent portfolio covering a combination therapy of Fluorouracil and Calcipotriene for Actinic Keratosis treatment, aligning with recent American Academy of Dermatology guidelines on field-directed therapy.